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implications of heart disease on pregnancy. Appropriate advice and
information likely fluctuates in accordance with cardiac or hemo-
dynamic changes across time. There are several models to address
this issue, including a collaborative approach between adult CHD
and contraception clinics and the incorporation of contraception
and pregnancy counseling by advanced practice nurses within
CHD clinics. Responsible health care professionals working with
women with CHD will provide information and guidelines, but
final decision-making lies with patients and must be respected,
even if it differs from medical advice.
This study has limitations. Because guidelines relating to preg-
nancy and contraception in women with CHD are not evidence-
based, it is important that physicians weigh the risks and benefits for
each individual. This study investigated patient-recalled information
versus physician-provided information, as no data were available
regarding the exact nature of the advice provided to women.
In conclusion, many women with CHD lack adequate knowl-
edge regarding contraception and pregnancy risks. Accurate and
continuing education should be a priority in order to ensure that
both patients and healthcare professionals have access to the most
current information.
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Letters to the Editor
Editor’s Note
Our usual policy at JACC is to limit Letters to the Editor
and their replies to a total of 400 words. However, we have
recently encountered 2 letters which considerably exceeded
this limit and provoked replies of similar length. Both
interchanges dealt with issues of substantial current interest
and importance: the role of intervention following infarc-
tion, particularly for patients with total coronary occlusion,
and the role of percutaneous intervention versus surgery for
unprotected left main coronary stenosis. Therefore, we have
decided to make an exception and to publish the letters and
replies as submitted. We believe that a thorough airing of
these topics more than justifies this exception.
A Meta-Analysis
That Misses the Mark
In the February 7, 2008, issue of the Journal, Abbate et al. (1)
present a meta-analysis with a stated goal of including randomized
controlled trials of late percutaneous coronary intervention (PCI)
of the infarct-related artery (IRA) in stable patients 12 h after
onset of myocardial infarction (MI) (1). A fundamental principle
of meta-analysis is inclusion of all studies that meet stated
eligibility criteria with common end point definitions. The meta-
analysis should address a relevant clinical question. Whether totally
occluded IRAs should be opened in stable patients late after MI
onset (the late open artery hypothesis) is an important question,
and the authors introduce this concept early in the report.
However, of the 10 studies included in the Abbate et al. (1)
analysis, only 6 set out specifically to test the late opening of
occluded IRA hypothesis, while 4 studies (TOPS [Treatment of
Post-Thrombolytic Stenosis], BRAVE 2 [Beyond 12 Hours
Reperfusion Alternative Evaluation], SWISSI II [Swiss Interven-
tional Study on Silent Ischemia Type II], and ALKK [Arbeitsge-
meinschaft Leitende Kardiologische Krankenhausärzte]) were ex-
amining whether or not to perform PCI in patients beyond the
acute phase of MI when the IRA was often patent after fibrinolytic
therapy or patients were randomized in order to evaluate a global
invasive versus selective, ischemia-driven, invasive care strategy
(the BRAVE 2 trial). For example, the BRAVE 2 trial is not
applicable to address the late open artery hypothesis, since one-half
of those enrolled in the BRAVE 2 trial did not have initial
angiography, one-half of those with angiograms had open arteries,
and PCI, coronary artery bypass grafting, or no procedure was
performed in the invasive group. The SWISSI II trial selectively
enrolled patients with silent ischemia and 1- to 2-vessel disease,
with no information on the status of the IRA provided, up to 3
months after ST-segment elevation myocardial infarction
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(STEMI) or non–ST-segment elevation myocardial infarction
(NSTEMI) and was included despite the entry criterion of 60 days
post-MI noted in the meta-analysis abstract.
By the authors’ report, 16% of the patients in the meta-analysis
had open IRAs at initial angiography. While the OAT (Occluded
Artery Trial) study provided 60% of the total population, and all
IRAs in the OAT study were occluded, 40% of the non-OAT
study patients added to form this meta-analysis represent a
different population, not addressing the open artery hypothesis. If
the authors had wanted to address a different topic—late revascu-
larization in all patients (with closed or open IRAs) after STEMI
and NSTEMI—they could have included thousands of additional
patients in post-MI revascularization studies worldwide. This
exclusion of numerous other eligible studies with thousands of
patients enrolled in trials of PCI versus medical therapy only, or an
invasive strategy versus conservative strategy for post-STEMI
(after fibrinolytic therapy, with open or closed IRAs after MI), or
NSTEMI that meets their criteria is not consistent with meta-
analytic principles. In addition to the numerous sources of heter-
ogeneity cited, the studies spanned too great a time, introducing
additional heterogeneity in regard to advances in concomitant
medical therapies that have been shown to prolong life. Our
analysis of the studies selected by Abbate et al. (1) reveals such a
degree of heterogeneity (p  0.001) as to cast doubt on the
scientific validity of the meta-analysis above and beyond the
problems cited in the previous text with study selection. Recog-
nizing the different pathophysiology and evidence bases for assess-
ment of interventional management of the wide variety of post-MI
patients included in the Abbate et al. (1) meta-analysis, the
American College of Cardiology/American Heart Association
guidelines have separate recommendations for those with open
versus closed arteries, and based on ischemia, coronary anatomy,
stress testing, and left ventricular (LV) function (2,3). Indeed, the
clinical heterogeneity of all patients post-MI is simply not suitable
to a one-size-fits-all approach.
The Abbate et al. (1) meta-analysis of the LV ejection fraction
and volume end points also has substantial flaws. Relevant studies
that showed no benefit or harm from PCI, such as the second
randomization cohort of the TAMI-6 (Thrombolysis and Angio-
plasty in Myocardial Infarction-6) trial (4) and the TOAT (The
Open Artery Trial) study (5), were excluded. The TAMI-6 trial
was apparently excluded because it allowed randomization 12 h
after symptom onset (which the PCI portion of the protocol did
not—mean symptom to randomization time was 25 h). The
TOAT study had paired data between 6 weeks and 1 year and
showed harm from PCI; this study was apparently excluded
because the first echocardiogram was obtained at 6 weeks post-MI,
even though this timing of the first echocardiogram was not a
pre-specified exclusion criterion. Most importantly, several of the
included studies did not report paired change data (i.e., change
data for patients with both a baseline and follow-up value) for LV
ejection fraction or end-systolic and -diastolic volume indexes, but
rather reported the means of all baseline values and all follow-up
values, with different numbers of observations in each. Some
studies had between-group imbalances in missing data. In the
Horie et al. (6) study, for example, while all patients underwent
follow-up LV function assessment, only 17 of 39 (44%) no-PTCA
and 32 of 44 (73%) PTCA patients had this assessment at baseline.
Similarly, in the SWISSI II trial, only 69 of 105 (72%) of PCI and
38 of 105 (36%) of drug therapy patients underwent follow-up LV
function assessment. Yet Abbate et al. (1) appear to have con-
structed the difference in mean change between the 2 groups by
subtracting the baseline and follow-up values of each group and
then calculating the difference between these. This procedure is
highly fraught with the risk of misleading results due to selection
bias. For example, a study could have all patients with a baseline
ejection fraction, but only the healthier ones return to obtain a
follow-up value. Even if there is no change from baseline to
follow-up in individual patients, the means will appear to show an
improvement because sicker patients were included in the baseline
mean (reducing that mean) but were excluded from the follow-up
mean (so that only the values of healthier patients were included in
that mean). The use of unpaired values or subtracting means to
obtain a difference in “change” renders the analysis invalid. No
imputation technique can correct for 64% (and imbalanced)
missing data. Finally, Table 4 of their paper, which the text refers
to as supporting the validity of the analysis, is not in the
publication. Perhaps that demonstrated that some patient level
paired data were obtained instead of sole reliance on published
aggregate data.
Other errors that warrant correction include incorrect data
reported for the TOMIIS (Total Occlusion Post-Myocardial
Infarction Intervention Study) trial and the TOPS trial in Tables
2 and 3 of their paper, incorrect 95% confidence intervals for the
TOMIIS trial in Figure 2 of their paper, and an incorrect number
of total deaths (there are 6 not 3) in the interventional arm of the
SWISSI II trial used in the risks of outcomes analysis illustrated in
Figure 1 of their paper.
The authors raise a methodological issue in their discussion of
the OAT study and its angiographic ancillary study the TOSCA-2
(Total Occlusion Study of Canada) trial (7,8) that also merits
clarification. Abbate et al. (1) state that the OAT study results
were marred by “construction” of the survival curves. All survival
curves in the OAT study were based on the commonly accepted
Kaplan-Meier product-limit estimates of survival probabilities (9).
The OAT study used the Kaplan-Meier procedure because of the
existence of different lengths of follow-up among the patients. The
Kaplan-Meier procedure must be utilized to analyze survival data;
the use of simple proportions of events (ignoring different lengths
of follow-up and times to events) can lead to inaccurate and
potentially misleading results. While the authors are correct that
the relatively small number of patients (533 at 4 years [7]) available
for long-term analysis in the OAT study could underestimate a
potential late benefit from PCI, it could just as easily underesti-
mate late harm. The addition of substantially smaller studies to this
meta-analysis that set out to answer a different question and that
deals with a different patient population cannot possibly correct
this potential deficiency. Only long-term follow-up of the full
OAT study cohort or cohorts of other studies specifically testing
the open artery hypothesis can do this, and the OAT study is, in
fact, currently in a long-term follow-up phase.
In this regard, however, Abbate et al. (1) violate another
meta-analytic principle by using very different lengths of follow-up
in the analysis. The technique utilized by the authors for calculat-
ing a simple proportion of mortality based on the number of
patients dead divided by the number of patients in the study (or
treatment arm) can create a serious bias in reporting a long-term
study. When deaths occur at any point over a several-year
follow-up period and there are censored data throughout the
period, the simple proportion of mortality will underestimate the
hazard rate in a long-term clinical trial. Depending on the joint
distribution of deaths and censored observations, a substantial
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underestimate can be created. Using estimates from a long-term
trial creates a downward bias in the event rates and potentially
affects the results and interpretation of a meta-analysis. Further-
more, potential imbalances in the pattern of events and censoring
will change the relative rates between the 2 groups.
A meta-analysis of all open artery hypothesis trials is certainly
reasonable, although the OAT and TOSCA-2 studies will dom-
inate such analyses of clinical outcomes and function respectively
because of their large numbers. A recently published meta-analysis
of the 6 trials that included only studies of patients with total
occlusions showed no effect of the study intervention on death,
MI, heart failure, or their composite (10). The Abbate et al. (1)
meta-analysis, with its selective inclusion and exclusion of studies,
methodological limitations of aggregate, nonpatient level data, and
the marked and statistically significant heterogeneity of popula-
tions, duration of follow-up and of treatment effect, contributes
little to inform medical practice.
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Reply
We welcome the letter of Dr. Džavı´k and colleagues and other
OAT (Occluded Artery Trial) study investigators in reference to
our recently published report (1) as it presents an occasion to
discuss, in a scholarly manner, the benefits of late revascularization
of the infarct-related artery (IRA) in patients with acute myocar-
dial infarction (AMI).
While Dr. Džavı´k and colleagues state that our meta-analysis
“misses the mark,” we conversely believe that they may have missed
the point of our analysis. This meta-analysis is not meant to be an
alternative to the OAT study but rather an integration of available
information to medical practice with a diverse assessment of the
question of whether revascularization of the IRA should be
attempted in patients presenting 12 h after AMI. This study is
not meant specifically to investigate whether there is a clinical
correlate to the “open artery hypothesis” (2), although in some
ways its findings support such hypotheses.
The OAT study (3) was designed to clinically test the “open artery
hypothesis” but failed to show any benefit or harm from late
revascularization. Enrollment, however, was stopped early, events
were fewer than anticipated, median follow-up was3 years, and the
cardiology community expressed concerns regarding the applicability
of the results to real-life scenarios. No detailed registry of the screened
patients has been taken in order to appraise the external validity of the
trial and compare outcomes of randomized versus nonrandomized
patients. It is unclear whether many occlusions that were deemed
feasible and functionally important were immediately attempted (thus
excluding them from randomization), with potentially less ideal
candidates available for randomization.
Approximately 1 year after publication of the OAT study, the
SWISSI II (Swiss Interventional Study on Silent Ischemia
Type II) study (4) showed a survival benefit for patients with
inducible ischemia after AMI randomized to late revasculariza-
tion of the IRA. Therefore, we attempted to put these disparate
results into perspective using the meta-analytic technique with the
belief that inclusion of multiple trials in the meta-analysis may
reduce the enrollment bias by including more investigators and
different patient pools, including patients with different degrees of
IRA stenosis.
We agree that our analysis is characterized by heterogeneity
among studies but we see this not as a flaw in the design but rather
an opportunity to detect differences in study designs, study
population, and, ultimately, results. We included in the analysis 10
studies randomizing patients to late revascularization of the IRA or
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